Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down14.860 -0.440 (-2.876%)
Research Report

16/04/2020 14:02

{I-bank focus}Nomura lowers CSPC Pharma (01093) to HK$24

[ET Net News Agency, 16 April 2020] Nomura lowered its target price for CSPC
Pharmaceutical Group (01093) to HK$24 from HK$25.9 and maintained its "buy" rating.
The research house expects 1Q earnings to record a moderate decline, followed by a
strong rebound in 2Q. According to the local National Health Commission (NHC), patient
visits in both Shanghai and Guangdong have recovered by more than 70% as of late
March/early April, suggesting accelerated growth of hospital pharmaceutical sales across
Nomura also sees continued momentum in API (active pharmaceutical ingredient) prices
(year-to-date +35% for vitamin C and 45% for penicillin G). It forecast earnings to grow
by 21% for 2020, mainly driven by sales growth of current blockbusters and rebounding API.

Remark: Real time quote last updated: 25/09/2020 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.